Search Results - "Shcherbinin, Dmitry N"

Genetic Passive Immunization with Adenoviral Vector Expressing Chimeric Nanobody-Fc Molecules as Therapy for Genital Infection Caused by Mycoplasma hominis by Burmistrova, Daria A, Tillib, Sergey V, Shcheblyakov, Dmitry V, Dolzhikova, Inna V, Shcherbinin, Dmitry N, Zubkova, Olga V, Ivanova, Tatiana I, Tukhvatulin, Amir I, Shmarov, Maxim M, Logunov, Denis Y, Naroditsky, Boris S, Gintsburg, Aleksandr L

“…Developing pathogen-specific recombinant antibody fragments (especially nanobodies) is a very promising strategy for the treatment of infectious disease…”
Get full text

Mutations in the genome of avian influenza viruses of the H1 and H5 subtypes responsible for adaptation to mammals by Timofeeva, Tatiana A., Rudneva, Irina A., Lomakina, Natalia F., Timofeeva, Elena B., Kupriyanova, Irina M., Lyashko, Alexsander V., Shcherbinin, Dmitry N., Shilov, Alexsander A., Shmarov, Maksim M., Ryazanova, Elena L., Mochalova, Larisa V., Timofeev, Boris I.

“…Avian influenza viruses of the H1 and H5 subtypes were involved in the formation of highly pathogenic viruses that caused pandemics and panzootics in the…”
Get full text

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia by Logunov, Denis Y, Dolzhikova, Inna V, Shcheblyakov, Dmitry V, Tukhvatulin, Amir I, Zubkova, Olga V, Dzharullaeva, Alina S, Kovyrshina, Anna V, Lubenets, Nadezhda L, Grousova, Daria M, Erokhova, Alina S, Botikov, Andrei G, Izhaeva, Fatima M, Popova, Olga, Ozharovskaya, Tatiana A, Esmagambetov, Ilias B, Favorskaya, Irina A, Zrelkin, Denis I, Voronina, Daria V, Shcherbinin, Dmitry N, Semikhin, Alexander S, Simakova, Yana V, Tokarskaya, Elizaveta A, Egorova, Daria A, Shmarov, Maksim M, Nikitenko, Natalia A, Gushchin, Vladimir A, Smolyarchuk, Elena A, Zyryanov, Sergey K, Borisevich, Sergei V, Naroditsky, Boris S, Gintsburg, Alexander L

“…A heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V), showed a good safety profile and induced strong humoral and cellular…”
Get full text

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia by Logunov, Denis Y, Dolzhikova, Inna V, Zubkova, Olga V, Tukhvatulin, Amir I, Shcheblyakov, Dmitry V, Dzharullaeva, Alina S, Grousova, Daria M, Erokhova, Alina S, Kovyrshina, Anna V, Botikov, Andrei G, Izhaeva, Fatima M, Popova, Olga, Ozharovskaya, Tatiana A, Esmagambetov, Ilias B, Favorskaya, Irina A, Zrelkin, Denis I, Voronina, Daria V, Shcherbinin, Dmitry N, Semikhin, Alexander S, Simakova, Yana V, Tokarskaya, Elizaveta A, Lubenets, Nadezhda L, Egorova, Daria A, Shmarov, Maksim M, Nikitenko, Natalia A, Morozova, Lola F, Smolyarchuk, Elena A, Kryukov, Evgeny V, Babira, Vladimir F, Borisevich, Sergei V, Naroditsky, Boris S, Gintsburg, Alexander L

“…We developed a heterologous COVID-19 vaccine consisting of two components, a recombinant adenovirus type 26 (rAd26) vector and a recombinant adenovirus type 5…”
Get full text

An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults by Tukhvatulin, Amir I., Dolzhikova, Inna V., Shcheblyakov, Dmitry V., Zubkova, Olga V., Dzharullaeva, Alina S., Kovyrshina, Anna V., Lubenets, Nadezhda L., Grousova, Daria M., Erokhova, Alina S., Botikov, Andrei G., Izhaeva, Fatima M., Popova, Olga, Ozharovskaia, Tatiana A., Esmagambetov, Ilias B., Favorskaya, Irina A., Zrelkin, Denis I., Voronina, Daria V., Shcherbinin, Dmitry N., Semikhin, Alexander S., Simakova, Yana V., Tokarskaya, Elizaveta A., Shmarov, Maksim M., Nikitenko, Natalia A., Gushchin, Vladimir A., Smolyarchuk, Elena A., Zubkova, Tatiana G., Zakharov, Konstantin A., Vasilyuk, Vasiliy B., Borisevich, Sergei V., Naroditsky, Boris S., Logunov, Denis Y., Gintsburg, Alexander L.

“…While the world is experiencing another wave of COVID-19 pandemic, global vaccination program is hampered by an evident shortage in the supply of licensed…”
Get full text

Development of Neutralizing Nanobodies to the Hemagglutinin Stem Domain of Influenza A Viruses by Voronina, D V, Shcheblyakov, D V, Esmagambetov, I B, Derkaev, A A, Popova, O, Shcherbinin, D N

“…The influenza virus infection claims ~650,000 lives annually. Taking into account the evolving resistance of the pathogen to antiviral drugs and the waning…”
Get full text

Genetic Passive Immunization with Adenoviral Vector Expressing Chimeric Nanobody-Fc Molecules as Therapy for Genital Infection Caused by Mycoplasma hominis: e0150958 by Burmistrova, Daria A, Tillib, Sergey V, Shcheblyakov, Dmitry V, Dolzhikova, Inna V, Shcherbinin, Dmitry N, Zubkova, Olga V, Ivanova, Tatiana I, Tukhvatulin, Amir I, Shmarov, Maxim M, Logunov, Denis Y

“…Developing pathogen-specific recombinant antibody fragments (especially nanobodies) is a very promising strategy for the treatment of infectious disease…”
Get full text